Novartis AG NVS

On Sept. 1, 2026, the Wall Street Journal reported that Novartis paused eight rap-cel trials across autoimmune and neurological diseases after three patients died from immune effector cell-associated hemophagocytic syndrome. Bristol Myers Squibb separately paused enrollment in its competing CAR-T program, zola-cel, citing transient inflammatory events but no deaths. Novartis keeps two oncology rap-cel trials in lymphoma and leukemia active, creating a split between autoimmune safety concerns and established cancer use. Investigators are examining whether manufacturing or dosing issues contributed to adverse reactions, and safety reviews could lead to revised protocols, dosing, or longer follow-ups. Regulators may demand heightened monitoring and tighter trial controls, potentially delaying approvals and dampening long-term pipeline value. Hedge funds show mixed sentiment; investors should treat autoimmune rap-cel as highly uncertain until cause and restart plans are clarified. Three deaths and an eight-trial pause significantly elevate safety, regulatory, and pipeline risk for Novartis's autoimmune CAR-T program, likely affecting near- to mid-term performance.

Artisan Partners, among Novartis's top 20 shareholders, calls for a board shake-up to tighten oversight of acquisitions after the Swiss drugmaker's stock dropped 11% in a week, erasing about $30 billion in value and following back-to-back trial failures, including pelacarsen. David Samra said 'the party is over' and urged Chairman Giovanni Caforio to empower a dedicated acquisition committee and stronger deal vetting, while saying Vas Narasimhan has done a good job since 2018. The push targets governance rather than leadership, aiming to fix M&A discipline without disrupting strategy. The $12 billion Avidity acquisition remains with other programs beyond del-desiran, which failed Phase III. Novartis emphasized a broad pipeline, unchanged guidance, and remibrutinib progress in MS. Hedge funds increased exposure before the sell-off; the company faces renewed scrutiny of capital allocation and future deal-making. Governance pressure and scrutiny of acquisitions could significantly alter Novartis's deal-making and capital-allocation strategy.

Roche is pressing Novartis in the IgA nephropathy race after a Phase III trial of sefaxersen met its primary endpoint. In the IMAgINATION study (NCT05797610), interim data showed a statistically and clinically meaningful reduction in proteinuria (24-hour UPCR) at 37 weeks versus placebo, a marker linked to slower kidney function decline. The trial will continue blinded to assess two-year kidney function by eGFR at week 105. Roche plans to present interim Ionis-partnered data at a medical congress and seek accelerated approval based on the 37-week results. IgAN, a chronic autoimmune disease, can progress to end-stage kidney disease in up to 50% of patients within 20 years. Separately, Novartis gained FDA approval for Fabhalta (iptacopan) to slow kidney function decline in adults with IgAN at risk of progression in July 2026, marking the first complement factor B inhibitor approved. Roche's Phase III success and potential accelerated approval threaten Novartis' IgAN franchise and market position.

MSD's diabetic macular edema therapy remigromig (EyeBio) posted non-inferior efficacy to Lucentis (ranibizumab) in BRUNELLO (NCT06571045) across 984 adults, using two once-monthly doses (0.5 mg and 0.8 mg). The result supports a potential new mechanism—Wnt agonism—for DME, possibly challenging the anti-VEGF-dominated market if safety is acceptable. However, higher rates of treatment-related adverse events, including vitreous haemorrhage and proliferative diabetic retinopathy, led to more discontinuations in the remigromig arms, prompting MSD to plan further analyses. Despite tolerability questions, remigromig could benefit about 40% of DME patients who do not fully respond to current therapies such as Lucentis or Eylea. Analysts see Wnt agonism as a meaningful validation; MSD acquired remigromig through its 2024 EyeBio takeover. The broader DME market was $4.42B in 2024, with 3.4% CAGR to 2034. A non-inferior efficacy with potential safety risks could erode Novartis's DME franchise if remigromig reaches the market.

Vertex Pharmaceuticals is pursuing diversification beyond CF, leveraging its CFTR franchise to fund a kidney-disease push. The renal portfolio includes VX-407 for autosomal dominant polycystic kidney disease (ADPKD), inaxaplin for AMPK? (AMKD), and povetacicept for IgA nephropathy (IgAN) and primary membranous nephropathy (pMN). Povetacicept, bought with Alpine Immune Sciences for about $4.9 billion, targets BAFF and APRIL to address B-cell–mediated diseases. In RAINIER, povetacicept showed rapid, deep, sustained proteinuria improvement; FDA accepted IgAN filing in June 2026 with a decision due by November 30, 2026, a potential major catalyst. If approved, it would be Vertex’s first marketed nephrology product, addressing an estimated 330,000 IgAN patients in the US/Europe and over 1.5 million globally. Inaxaplin AMKD data from AMPLITUDE show a 42.7% UACR reduction at week 13 (modest proteinuria) and 17.3% reduction in AMKD with type II diabetes. IgAN competition includes Otsuka, Vera Therapeutics, and NVS’s atrasentan. IgAN regulatory decision and Vertex’s nephrology push could significantly alter nephrology competition and impact peers like NVS.

Novartis (SWX:NOVN) has signed an exclusive global license with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset, granting worldwide rights to develop and commercialise BoomRay within its radiopharmaceuticals pipeline. The deal adds another early-stage oncology candidate to Novartis' RLT efforts and reinforces the company's push to diversify beyond traditional small molecules into technically demanding, targeted therapies. While the asset is preclinical and carries scientific and regulatory risk, the move fits Novartis' strategy to bolster a broader radiopharmaceutical portfolio to offset patent expiries and pricing pressures across oncology. Investors should monitor progress into first-in-human studies, initial safety readouts, and whether BoomRay is prioritized within the company's RLT slate. The article notes a warning signal and contextualizes the deal within wider AI-stock and healthcare trend discussions. Expands radioligand therapy portfolio with a preclinical asset, offering potential long-term value but limited near-term impact due to early-stage status.

Novartis AG's Phase 3 Lp(a)HORIZON trial failed to show a major reduction in cardiovascular events despite pelacarsen achieving substantial Lp(a) lowering. The miss raises questions about how much Lp(a) must be lowered, how long treatment must run, and whether different approaches can deliver meaningful outcomes, reshaping the competitive landscape for Lp(a)-lowering programs. Citi says the result could push CRISPR Therapeutics to prioritize CTX321, a more potent, next-generation candidate, over CTX320, while noting limited immediate downside for Ionis Pharmaceuticals, which developed pelacarsen. Ionis' momentum in Lp(a)-driven disease may still be tested, but the readout is seen as a resetting of expectations rather than a verdict on the broader platform. CRISPR is expected to update on CTX321 in 2026; investors should watch for whether future therapies translate biomarker lowering into real patient benefits. Pelacarsen's failure to translate Lp(a) lowering into cardiovascular benefits creates uncertainty around Novartis's Lp(a) strategy and could shift competitive dynamics in the space.

Ionis Pharmaceuticals announced positive late-stage results from two partnered phase III programs. In FUSION, ulefnersen met the primary endpoint for functional impairment and survival at 72 weeks in FUS-ALS; data will be presented later, and Otsuka plans expedited regulatory submission. In IMAgINATION, sefaxersen met its interim primary endpoint in IgA nephropathy, showing statistically significant reductions in proteinuria after 37 weeks; long-term kidney function will be evaluated through week 105 under Roche's oversight. Ionis and Roche licensed sefaxersen in 2022, and Ionis remains eligible for milestones and royalties. The updates follow Ionis’ recent setbacks in two other partnered programs with AstraZeneca and Novartis, but Ionis also recently won FDA approval for Zanvastro for Alexander disease, signaling ongoing momentum in its neurology portfolio. Novartis' potential royalties and strategic upside from the pelacarsen program face a meaningful setback as Lp(a)HORIZON failed in phase III.

BoomRay Pharmaceuticals and Novartis signed an exclusive worldwide license for an undisclosed preclinical radioligand therapy asset, worth up to $900 million, including upfront payments and potential development, regulatory, and sales milestones plus royalties on global net sales. BoomRay brings RLT discovery, radiochemistry, and clinical translation capabilities; Novartis contributes global commercialization and radiopharmaceutical expertise. The deal aims to accelerate the asset toward patients and expand Novartis' RLT portfolio. CEO Bo Shan hailed the agreement as a milestone validating BoomRay’s capabilities, while Novartis leadership framed it as leveraging external innovation to advance breakthrough therapies. Financial adviser BFC Group supported BoomRay. The context includes Novartis’s May 2024 acquisition of Mariana Oncology for up to $1.75 billion in potential milestones, underscoring commitment to radiopharmaceuticals. Exclusive license for a high-upside preclinical RLT asset signals a meaningful long-term expansion of Novartis' radiopharma capabilities.

Roche Holding reported that sefaxersen reduced urinary protein, a marker of kidney damage, more than placebo in a Phase 3 trial after 37 weeks, with no new safety signals. The study will continue to week 105 to see if early protein reductions translate into lasting kidney protection. Roche plans to discuss interim findings with regulators. The opportunity is real, but the hurdle remains; Novartis already has an approved treatment targeting the same protein, potentially placing Roche in competition on a similar mechanism. Roche shares slipped about 1.0% to $55.11, and the stock trades roughly 33% above its GF Value, indicating investor premium despite uncertain long-term benefits. GuruFocus notes seven warning signs on RHHBY. The ultimate verdict will hinge on longer-term results showing durable kidney function preservation. Roche's interim kidney-trial signal against a target relevant to Novartis could shift competitive dynamics and sentiment, but long-term outcomes are decisive.

BoomRay Pharmaceuticals Ltd. signed an exclusive global license with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset. The deal combines BoomRay’s discovery and development capabilities with Novartis’ global RLT leadership to advance the asset toward patients worldwide. BoomRay can receive up to USD 900 million in upfronts, development, regulatory, and sales milestone payments, plus royalties on future global net sales. BoomRay’s CEO Bo Shan says the agreement validates its capabilities and accelerates path to patients. Novartis’ Global Head of Oncology, Biomedical Research, Shiva Malek, says the collaboration enhances Novartis’ RLT portfolio by pairing external innovation with internal R&D. BFC Group advised BoomRay on the transaction. BoomRay positions itself as a clinical-stage firm pursuing first-in-class or best-in-class radiopharmaceuticals, with a pipeline spanning candidate discovery, radiochemistry, and clinical translation. Exclusive global license of a preclinical radioligand therapy asset with up to $900 million in milestones expands Novartis' RLT portfolio and signals meaningful strategic value.

Novartis discontinued VHB937 (lifonebart), its mid-stage ALS drug targeting TREM2, after Phase II failed to meet primary and secondary endpoints in 251 patients. The program is ended for ALS but VHB937 remains in Alzheimer's disease trials. The setback follows recent Phase III failures for pelacarsen and del-desiran, fueling investor scrutiny of Novartis's pipeline and M&A strategy after spending about $12 billion on Avidity. Near-term revenue is unlikely affected since VHB937 was experimental, but the attrition heightens the burden to replace aging products and fund later-stage programs. Core growth remains supported by Kisqali, Kesimpta, Scemblix, Pluvicto, Leqvio, and remibrutinib's positive Phase III data, yet execution risk and fewer high-impact launches raise the importance of the remaining pipeline to the 5-6% five-year sales CAGR target. Consecutive pipeline setbacks erode growth prospects and increase the risk of failing to replace aging revenues.

Novartis announced that the EU's CHMP issued a positive opinion recommending marketing authorization of Cosentyx (secukinumab) for polymyalgia rheumatica (PMR) in adults who inadequately respond to steroids or relapse during tapering. Cosentyx, an IL-17A inhibitor, is already approved for PsA, plaque psoriasis, AS, non-radiographic axial SpA, and hidradenitis suppurativa, with pediatric indications as well. The CHMP's backing is supported by the REPLENISH Phase III trial, in which patients received Cosentyx 300 mg or 150 mg or placebo with a 24-week steroid taper and achieved complete sustained remission and other endpoints through week 52. If the European Commission approves, Cosentyx would be the first IL-17A inhibitor approved in Europe for PMR. The EC decision is expected in about two months. Cosentyx sales were $3.4 billion in the U.S. (up 7%), with ex-US growth in Europe and most emerging markets. Broadens Cosentyx’s EU indication and potential sales, potentially improving growth prospects amid regulatory approvals and competitive pressures.

Novartis disclosed that pelacarsen failed to reduce heart attacks or strokes in high-risk patients, a setback for Lp(a)-lowering therapies. Amgen’s stock slid about 9% on the news, as investors questioned whether the Lp(a) drug class can deliver cardiovascular benefits. Morgan Stanley argues the market reaction may be too harsh; management noted olpasiran delivers far deeper Lp(a) reduction than pelacarsen and targets a higher-risk population in Phase 3, potentially altering required outcomes. Amgen’s pipeline, including MariTide and dazodalibep, remains pivotal to its growth, while the company continues to rely on Repatha and other products for current profits. Full pelacarsen data from Novartis is awaited at cardiology meetings, but the broader takeaway is ongoing skepticism about Lp(a) therapies despite substantial Lp(a) reductions. Pelacarsen failure undermines Novartis's Lp(a) strategy and could dampen future revenue from this class.

Novo Nordisk shares fell more than 7% to $39.82 after long-term targets failed to reassure investors about competition in the weight‑loss drug market. The company aims to launch more than five multi‑blockbuster drugs by 2030 and target over 150 billion Danish kroner in risk‑adjusted pipeline sales by 2035, including current assets. It expects 2026–2030 revenue growth in line with peers. CEO Mike Doustdar warned semaglutide’s key patent protection will erode in the early 2030s, with US exclusivity expiring in 2032—the market last year accounted for more than half of sales. CagriSema delivered 23% weight loss, below Lilly’s 25.5% and failing to meet non‑inferiority. Semaglutide accounts for about 75% of 2026 sales, leaving Novo exposed as major patents run out from 2030. In Q2, Novo held ~39% of the obesity market vs Lilly’s 61%. Patents expiry and rising competition could moderately affect Novo Nordisk’s trajectory, influencing market sentiment around peers like Novartis.

Novartis assumes full control of a brain delivery platform. Platform ownership expands Novartis neurological delivery options without altering core trajectory.

Novartis receives positive CHMP opinion for Cosentyx in polymyalgia rheumatica (PMR). Positive CHMP opinion advances Cosentyx toward potential EU approval for new PMR indication.

Novartis suffers third drug trial setback in a week, triggering its worst trading day in years. Repeated clinical trial failures undermine Novartis drug pipeline and future revenue prospects.

Novartis and Ionis cholesterol drug failed to meet goals in late-stage trial. Late-stage failure of major cholesterol drug creates significant setback for Novartis pipeline and investor outlook.

Novartis will pay $125 million to acquire a blood-brain barrier crossing platform. Platform acquisition secures key technology for expanding Novartis central nervous system drug capabilities.

Novartis suffers another setback after two high-profile surprises hammer shares. Setbacks from high-profile surprises can moderately affect Novartis market performance and investor sentiment.

FDA clears first generic radioligand drug. Sionna turns to layoffs. First generic radioligand approval introduces direct competition to Novartis therapies.

Novartis disrupts multibillion-dollar drug race, with direct implications for Eli Lilly stock performance. Novartis move strengthens its position in key drug competition and shifts market dynamics against rivals.

Amgen shares fell 5% after doubts emerged over an Lp(a)-targeting drug that is not its own, putting related therapeutic bets in question and affecting market views on cardiovascular assets. Lp(a) drug concerns may shift sentiment around Novartis cardiovascular pipeline without altering core operations.

Novartis trial failure prompts Jim Cramer commentary on Amgen prospects. Novartis trial failure marks major setback in drug development pipeline with direct effects on future revenue and competitive standing.

Novartis executed $30 billion in deals, triggering boardroom conflicts over strategy and governance. $30 billion deal spree plus board reckoning indicates major strategic shifts likely to alter Novartis trajectory and investor views.

Novartis AG encounters drug trial setbacks that question the viability of its growth pipeline. Drug trial setbacks directly threaten Novartis pipeline and future revenue streams.

Novartis AG faces ongoing challenges that could lead to further difficulties, weighing on its operations, financial results and stock performance. Continued headwinds may affect near-term results and sentiment but are unlikely to alter Novartis' overall trajectory.

Amgen shares fell 10% after clinical trial results from a study the company did not run, highlighting competitive pressure in the sector involving Novartis AG (NVS). Competitor stock reaction to external trial data points to moderate shifts in market positioning for Novartis without altering core operations.

Eli Lilly advances immunology portfolio development to generate new growth beyond GLP-1 drugs. Eli Lilly immunology expansion increases competitive pressure on Novartis in overlapping therapeutic areas.